Nektar's $400M Boost Fuels Phase 3 Push for Autoimmune Drug

SAN FRANCISCO, CA – February 12, 2026 – Nektar Therapeutics has successfully priced an upsized $400 million public offering, a significant capital infusion that underscores investor confidence in the clinical-stage biotechnology company's promising immunotherapy pipeline. The move provides critical fuel for the late-stage development of its lead drug candidate, rezpegaldesleukin (REZPEG), positioning the company to advance into pivotal Phase 3 trials for chronic autoimmune diseases.

The offering, which was increased from its initial size due to strong demand, consists of 6.6 million shares of common stock priced at $58.00 per share, alongside a smaller number of pre-funded warrants. The gross proceeds are expected to provide Nektar with the financial runway needed to navigate the expensive final stages of clinical testing and manufacturing scale-up.

A Surge of Investor Confidence

The successful financing follows a dramatic surge in Nektar's stock (Nasdaq: NKTR), which skyrocketed over 50% earlier this week. The rally was ignited by the release of highly positive long-term data from a Phase 2b study of REZPEG in patients with atopic dermatitis, a common and often debilitating form of eczema. Shares jumped from a close of $37.07 on February 9 to open at $56.00 the next day, ultimately closing at $66.35 on February 11, marking a remarkable 76% year-to-date gain.

This market enthusiasm translated directly into the upsized offering and has been echoed by Wall Street analysts. In the wake of the clinical data, several investment firms upgraded their outlook on Nektar. HC Wainwright & Co. boosted its price target from $135 to an ambitious $165, while BTIG raised its target to $151, with analysts noting REZPEG's potential to become a first-line treatment. Piper Sandler reiterated its "Overweight" rating, and William Blair upgraded the company to "Outperform." The consensus among analysts points toward a strong belief in the drug's future, with an average price target hovering around $120 per share.

This optimism stands in contrast to Nektar's recent financial performance, which has been characterized by significant cash burn and a lack of profitability—common traits for a clinical-stage biotech. The company's ability to raise $400 million in this environment highlights a key trend: investors are selectively deploying capital, rewarding companies with compelling, de-risked clinical assets in high-need areas, even if their balance sheets show near-term stress. The institutional ownership of over 72% further reflects confidence from large, long-term investors.

The Promise of Rezpegaldesleukin

At the heart of the excitement is rezpegaldesleukin, a novel, first-in-class therapy designed to stimulate regulatory T cells (Tregs). Unlike many existing autoimmune treatments that broadly suppress the immune system, REZPEG aims to restore balance by boosting the body's own mechanism for controlling inflammation. This approach could offer a more targeted and potentially safer long-term treatment profile.

The recent one-year data from the REZOLVE-AD study in atopic dermatitis was a major validation of this approach. The results demonstrated not just efficacy, but durability. A remarkable 83% of patients receiving a quarterly dose maintained at least a 75% improvement in skin lesions (EASI-75) at the 52-week mark. Furthermore, over 20% of patients who showed an initial response had a chance of achieving completely clear skin (EASI-100) within a year—an outcome that could be a significant differentiator in a competitive market.

Crucially, the data suggests a highly convenient dosing schedule of once per month or even once per quarter, a stark contrast to more frequent injections required by some current blockbuster therapies. Armed with this robust data, Nektar plans to initiate a pivotal Phase 3 program for REZPEG in atopic dermatitis in the second quarter of 2026. If those trials succeed, the company anticipates filing for regulatory approval by 2029.

The potential for REZPEG extends beyond eczema. The drug is also in a Phase 2b trial for alopecia areata, an autoimmune disease causing hair loss, with topline data expected in the coming months. Positive results there could further bolster the case for REZPEG as a pipeline-in-a-product. Clinical trials are also underway for its use in Type 1 diabetes.

Financial Fortitude for the Road Ahead

The $400 million capital raise is not just a vote of confidence; it's a strategic necessity. Advancing a drug into Phase 3 trials is a vastly expensive undertaking, often costing hundreds of millions of dollars. Prior to the offering, Nektar held approximately $229.1 million in cash. While a solid figure, it would be insufficient to fully fund the comprehensive late-stage development and manufacturing preparations for REZPEG.

This new infusion of capital dramatically extends the company's operational runway, allowing it to execute its clinical plans without immediate financial pressure. The proceeds are earmarked for general corporate purposes, with a stated focus on research, clinical development, and manufacturing costs associated with its drug candidates. The offering was managed by a syndicate of prominent investment banks, including Jefferies, TD Cowen, and Piper Sandler, lending further institutional credibility to the transaction.

Navigating a Crowded Field

While the clinical data is promising, Nektar is entering a competitive landscape. The atopic dermatitis market is dominated by blockbuster drugs like Sanofi and Regeneron's Dupixent and AbbVie's Rinvoq. These established therapies have set a high bar for efficacy and have deep commercial entrenchment.

However, REZPEG's unique mechanism of action and potential for a best-in-class dosing schedule and safety profile could carve out a significant niche. By aiming to restore immune homeostasis rather than simply blocking inflammatory signals, it may offer a more fundamental and durable solution for patients. If the Phase 3 trials can replicate the impressive skin clearance and long-lasting control seen in Phase 2, Nektar could effectively challenge the current standard of care.

The upcoming data in alopecia areata will be the next major catalyst for the company. Success in a second major indication would substantially increase the perceived value of REZPEG and further validate Nektar's long-term strategy, turning this significant financial boost into a tangible new hope for patients with debilitating autoimmune diseases.